AFFYMETRIX MICROARRAY SYSEM

(调查员？S摘要)：随着人类的接近完成 基因组计划生物学研究的重点无疑将从 一种逐个基因的分析，以进行更全球化的基因表达研究。基金是 正在申请购买Affymetrix基因芯片系统 为了将这项技术引入细胞和分子生物学研究 勒纳研究所正在进行的项目，以补充 Affymetrix基因芯片寡核苷酸阵列系统已成为核心 服务。收购这种最先进的微阵列系统将 对勒纳研究中目前正在进行的许多研究项目的影响 研究所。该系统结合了几个独特的功能，将使 整个研究所的研究人员将扩展他们的基因表达谱 在各种不同的蜂窝系统中。目前，Affymetrix 寡核苷酸阵列正被用于发现模式以识别模式 在某些细胞类型和组织中的基因表达，以及高度 配对样本之间基因表达水平的定量比较。这个 CDNA微阵列系统的可用性将补充基因芯片的努力 通过允许个别研究人员使用基因或使用 完全从数据库中选择，或从数据库和 基因芯片预测。微阵列系统将被安置在基因中 Expression核心设施，将由核心员工运营和维护 确保生产高质量的定制设计阵列。研究人员在 克利夫兰诊所处于独特地位，与 临床人员允许访问各种患者材料和 确定许多有趣的和临床相关的疾病和 综合症。分析临床相关的全球基因表达的能力 疾病将极大地帮助识别涉及广泛的 各种医疗条件，并可能提出治疗目标。这个 快速识别与疾病状态相关的基因变化的能力将 也大大加深了我们对致病机制的理解 牵涉其中。生成定制cDNA阵列能力不仅将增强 正在进行的研究项目，但将激励开发新的途径 许多研究人员目前无法对生物系统进行分析 在他们的实验中追求特定的高通量基因图谱 系统。

(Investigator?s Abstract): With the near completion of the human genome project the emphasis in biological research will undoubtedly shift from a gene-by-gene analysis to more global studies of gene expression. Funds are being requested for the purchase of the Affymetrix cDNA microarray system in order to introduce this technology to cell and molecular biology research projects ongoing in the Lerner Research Institute and to complement the Affymetrix GeneChip oligonucleotide array system already available as a core service. The acquisition of this state-of-the art inicroarray system will impact on many researci projects currently underway in the Lerner Research Institute. The system combines several unique features that will empower researchers throughout the Institute to extend their gene expression profiling in a variety of different cellular systems. At present the Affymetrix oligonucleotide arrays are being used in a discovery mode to identify patterns of gene expression in certain cell types and tissues as well as to make highly quantitative comparisons in gene expression levels between paired samples. The availability of a cDNA microarray system would complement the GeneChip effort by allowing individual researchers to make custom arrays either using genes entirely selected from the databases or from a combination of database and GeneChip predictions. The microarray system will be housed in the gene expression core facility and will be operated and maintained by core staff ensuring the production of high quality custom designed arrays. Researchers at the Cleveland Clinic are in a unique position, in that close collaboration with clinical personnel allows access to a wide variety of patient material and identification of many interesting and clinically relevant diseases and syndromes. The ability to analyze global gene expression in clinically relevant disorders would aid significantly in identification of genes involved in a wide variety of medical conditions and possibly suggest therapeutic targets. The ability to rapidly identify genetic changes associated with disease states will also considerably further our understanding of the causative mechanisms involved. The capability to generate custom cDNA arrays will not only enhance ongoing research projects but will inspire the development of new avenues in the analysis of biological systems from many investigators currently not able to pursue specific high throughput gene profiling in their experimental systems.